LeMaitre Vascular completed the acquisition of Artegraft for $90m.

LeMaitre Vascular, a provider of devices and implants for the treatment of peripheral vascular disease, completed the acquisition of Artegraft, which processes and sells biologic vascular grafts, for $90m. "We are pleased to add Artegraft to our product offering, augmenting the suite of biologic and dialysis access products used by our core customer, the vascular surgeon. With this acquisition, we expect Artegraft to be the largest product line in our US sales bag and the cornerstone of our offering of devices used to treat patients with end-stage renal disease," Dave Roberts, LeMaitre Vascular President.